Despite facing significant challenges, InterCure Ltd. has managed to maintain resilience in its performance during the first half of 2024, as indicated by equity research conducted by Pablo Zuanic of Zuanic & Associates. The company exceeded revenue expectations, reporting 126 million NIS ($33.97 million), although it remains below pre-October 2023 levels of 414 million NIS, primarily due to the disruption at its southern Israeli facility occupied by the IDF.
InterCure has invested heavily in the restoration of its southern Israeli facility and anticipates a return to full operational capacity in the upcoming quarters. While reporting an EBITDA of 17.6 million NIS for H1 2024, which surpassed estimates, the inclusion of government compensation for conflict-related damages complicates direct comparisons. Despite the challenges, the company remains determined to achieve double-digit sales growth in the second half of 2024, with revenue expectations around 140 million NIS, albeit lower than initial estimates. InterCure aims to expand its market presence by launching over 30 new GMP SKUs in collaboration with renowned brands like Cookies, Binske, and Organigram OGI, with plans to introduce Cookies products in Germany by Q4 2024 alongside ongoing UK sales efforts.